Oncology Medical News about hepatocellular carcinoma;poor prognosis;Glypican-3 expression

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
Cancer Science, 06/05/09

Shirakawa H et al. - In a study to determine the expression profile of glypican (GPC)-3 in association with clinicopathological factors in hepatocellular carcinoma (HCC) pts and investigate the potential prognostic value of GPC3 by comparing the survival rate between GPC3-positive and GPC3-negative HCC pts, it was shown that GPC3 expression is correlated with a poor prognosis in HCC pts.

Methods

Primary HCC tissue samples (n=107) obtained from pts who had undergone hepatectomy between 2000 and 2001 were analyzed.

Results

GPC3 expression was less frequently observed in well-differentiated HCC than in moderately and poorly differentiated HCC, the difference in the frequency being statistically significant.
GPC3-positive HCC pts had a significantly lower 5-yr survival rate than the GPC3-negative HCC pts (54.5 vs 87.7%).
Among 80 of 107 (74.6%) pts with initial treatment who underwent hepatectomy, none of GPC3-negative HCC pts (n=16, 20.0%) died during follow-up.
No deaths were noted in the GPC3-negative HCC pts among the 71 (88.7%) pts with moderately and poorly differentiated HCC.
Multivariate analysis identified GPC3 expression as an independent prognostic factor for overall survival.